Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
Axatilimab + CAR-T in High-Risk Lymphoma
Age ≥ 18 years [+9]
KPS <60 [+9]
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Availability of a 5/10-8/10 mismatched (HLA-A, B, DR) haploidentical related don... [+3]
Poor cardiac function: LVEF <40% [+5]
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
First episode of systemic immunosuppression-requiring cGVHD, defined as classic... [+3]
Late persistent or recurrent aGVHD [+7]
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration... [+3]
Relative CNS disorders [+2]
Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.
Adults receiving first cycle of blinatumomab for relapse/refractory or MRD-posit... [+4]
Active CNS involvement by ALL [+5]
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match... [+2]
Poor cardiac function (LVEF <45%) [+7]
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.
Availability of 5/10 to 8/10 matched related donor [+2]
Poor cardiac, pulmonary, liver, and renal function [+3]
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.
Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have neg... [+7]
poor cardiac function (LVEF <40%) [+4]
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
presence of a TP53 mutation [+3]
KPS <60 [+10]